

PRESS RELEASE

Placement of shares issued by Med Life S.A. for which the pre-emption right is not exercised during the subscription period

17.11.2017

Med Life S.A. informs investors that it selected Wood & Company Financial Services a.s. to place the new shares to be issued by Med Life S.A. in the share capital increase for which the pre-emption right is not exercised (the "**Private Placement**"). The Private Placement will be carried out by way of a public offering exempted from the obligation to prepare and publish a public offering prospectus, in accordance with the applicable law.

We remind our investors that the Financial Supervisory Authority approved the Proportionate disclosure prospectus for the rights issue in respect of a maximum number of 2,600,000 new shares to be issued as a result of the share capital increase through cash contribution, **by way decision no. 1617 of 15.11.2017** (the "**Proportionate Disclosure Prospectus**"). The level of disclosure of the Proportionate Disclosure Prospectus is proportionate to this type of issue.

The Proportionate Disclosure Prospectus, together with the other documents that Med Life S.A. is required to make available to the investors, are published on the website of Med Life S.A. at <http://medlifeinternational.com> > Investors Relations. The Proportionate Disclosure Prospectus is also available on the website of SSIF Tradeville S.A., www.tradeville.eu, and on the website of Bucharest Stock Exchange www.bvb.ro.

Furthermore, we specify that the final subscription price of each newly issued share for which the pre-emption right is exercised during the first stage of the share capital increase in Med Life S.A. shall be determined by the Board of Directors, taking into account the sale price in the Private Placement for each newly issued share in respect of which the pre-emption right was not exercised, in accordance with the applicable law.

Read the Proportionate Disclosure Prospectus before subscribing!

The approval stamp applied on the public offering prospectus does not represent a guarantee or any type of appraisal by the Financial Supervisory Authority as regards the opportunities, advantages or disadvantages, profits or risks involved by the transactions to be concluded following the acceptance of the public offer subject of the approval decision. The approval decision certifies only that the prospectus complies with the requirements of the law and of the norms adopted in its application.

Mihail Marcu
Chairman of the Board of Directors